| 000 | 01627nam a22003617a 4500 | ||
|---|---|---|---|
| 008 | 191010s20192019 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a1092-8529 | ||
| 024 | _a10.1017/S1092852919001263 [doi] | ||
| 024 | _aS1092852919001263 [pii] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a31482777 | ||
| 245 | _aKeeping up with the clinical advances: tardive dyskinesia. [Review] | ||
| 251 | _aCns Spectrums. 24(S1):70-81, 2019 08. | ||
| 252 | _aCNS Spectr. 24(S1):70-81, 2019 08. | ||
| 252 | _zCNS Spectr. 24(S1):70-81, 2019 Aug. | ||
| 253 | _aCNS spectrums | ||
| 260 | _c2019 | ||
| 260 | _fFY2020 | ||
| 265 | _sppublish | ||
| 266 | _d2019-10-10 | ||
| 268 | _aCns Spectrums. 24(S1):70-81, 2019 Aug. | ||
| 520 | _aTardive dyskinesia (TD) was first described in 1964, but treatment for this sometimes poorly characterized condition lagged decades as it was labored by medico-legal implications. TD has often been lumped with other medication-induced disorders and incorrectly classified as extrapyramidal symptoms. TD is likely to be under-recognized for many of these reasons. Though diverse in its presentations, TD is distinct in terms of time course, pathophysiology, and phenomenology. | ||
| 546 | _aEnglish | ||
| 650 | _a*Tardive Dyskinesia/dt [Drug Therapy] | ||
| 650 | _aHumans | ||
| 650 | _aTardive Dyskinesia/di [Diagnosis] | ||
| 651 | _aMedStar Union Memorial Hospital | ||
| 657 | _aJournal Article | ||
| 700 | _aElkurd, Mazen T | ||
| 790 | _aBahroo L, Elkurd MT | ||
| 856 |
_uhttps://dx.doi.org/10.1017/S1092852919001263 _zhttps://dx.doi.org/10.1017/S1092852919001263 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c4634 _d4634 |
||